Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges

The value and utility of MRD in the management of adults with newly-diagnosed AML

Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance

Advances in immunotherapy for NHL: updates from iwNHL 2025

Reviewing recent guideline updates on the risk stratification and treatment of AML

The management of CLL in resource-limited settings: guideline development and ongoing projects

The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist

Understanding financial and time toxicity in cancer care: advice for community oncologists

Listener Q&A special: expert insights on CLL, myeloma, and lymphoma

Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025

Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials

FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD

Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial

iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more

Managing CNS lymphoma: expert insights and updates from ICML 2025

iwMDS wrap-up: translating research into practice to optimize patient care

Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification

Treating elderly or unfit patients with AML: current approach and future directions

Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!

CHIP & CCUS: advances in understanding and should we treat these precursor conditions?